Trial Profile
A Randomised, Multicentre, Investigator-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of MC2-01 Cream Compared to Vehicle and Active Comparator in Subjects With Mild-to-Moderate Psoriasis Vulgaris
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jul 2023
Price :
$35
*
At a glance
- Drugs Betamethasone-dipropionate/calcipotriol (Primary) ; Betamethasone-dipropionate/calcipotriol
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors MC2 Therapeutics
- 25 Jul 2023 Results of pooled post hoc analysis assessing the efficacy of CAL/BDP polyaphron dispersion (PAD)-cream in subgroups of patients with moderate-to-severe psoriasis from two completed phase 3 studies (NCT03308799 and NCT03802344) conducted in the USA and Europe, published in the Dermatology and Therapy.
- 24 Jul 2023 According to an Almirall S.A. media release, the company achieved sales of euro 7.7 MM in H1 2023, continuing to make solid progress since its launch last year. This treatment has already gained c.15% market share in Germany and c.19% share in Spain, and Almirall expects this solid traction to continue.
- 15 Sep 2022 Results published in the MC2 Therapeutics Media Release.